Neuropathy - Exponent of Accelerated Involution in Uremia: The Role of Carbamylation

1. Uremic neuropathy: an overview of the current literature REVIEW ARTICLE Rev. Assoc. Med. Bras. 2019 Feb;65(2):281-286.10.1590/1806-9282.65.2.28130892456Search in Google Scholar

2. Chillon J.M., Massy Z.A., Stengel B. Neurological complications in chronic kidney disease patients. Nephrol. Dial. Transplant. 2016 Oct;31(10):1606-14.10.1093/ndt/gfv31526359201Search in Google Scholar

3. Lau WL, Huisa BN, Fisher M.The Cerebrovascular- Chronic Kidney Disease Connection: Perspectives and Mechanisms.Transl Stroke Res. 2017 Feb;8(1):67-76.10.1007/s12975-016-0499-x524133627628245Search in Google Scholar

4. Lakshman SG, Ravikumar P, Kar G, Das D, Bhattacharjee K, Bhattacharjee P. A Comparative Study of Neurological Complications in Chronic Kidney Disease with Special Reference to its Stages and Haemodialysis Status. J Clin Diagn Res. 2016;10(12):OC01-OC04.10.7860/JCDR/2016/22815.8947529647428208901Search in Google Scholar

5. Vanholder R. et al. Review Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins. 2018; 10(1), 33.Search in Google Scholar

6. Lisowska-Myjak B. Uremic Toxins and Their Effects on Multiple Organ Systems. Nephron Clin Pract. 2014; 128:303-311.10.1159/00036981725531673Search in Google Scholar

7. Assem M, Lando M,Grissi M, Kamel S, Massy ZA, Chillon J, Hénaut L. The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders. Toxins. 2018; 10(7): 303.10.3390/toxins10070303607109230037144Search in Google Scholar

8. Vanholder R,Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins.J Am Soc Nephrol. 2008; 19: 863-870.10.1681/ASN.200712137718287557Search in Google Scholar

9. Gillery P, Jaisson S. Usefulness of non-enzymatic posttranslational modification derived products (PTMDPs) as biomarkers of chronic diseases, J. Proteomics. 2013; 228-238. 2013 Oct 30;92:228-38.Search in Google Scholar

10. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modificationderived products as biomarkers of molecular aging of proteins, Clin. Chem.56, 2010; 1401-1412. 2010 Sep;56(9):1401-12.Search in Google Scholar

11. S. Jaisson, A. Desmons, L. Gorisse, P. Gillery, Protein molecular aging: which role in physiopathology? Med. Sci. 2017 Feb;33(2):176-182.10.1051/medsci/2017330201328240209Search in Google Scholar

12. P. Gillery, S. Jaisson, Post-translational modification derived products (PTMDPs): toxins in chronic diseases? Clin. Chem. Lab. Med. 2014 Jan 1;52(1):33-8.10.1515/cclm-2012-088023454717Search in Google Scholar

13. D.R. Sell, M.A. Lane, W.A. Johnson, E.J. Masoro, O.B. Mock, K.M. Reiser, J.F. Fogarty, R.G. Cutler, D.K. Ingram, G.S. Roth, V.M. Monnier, Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence, Proc. Natl. Acad. Sci. U. S. A. 1996 Jan 9;93(1):485-90.10.1073/pnas.93.1.485402638552666Search in Google Scholar

14. R. Meerwaldt, J.W. Hartog, R. Graaff, R.J. Huisman, T.P. Links, N.C. den Hollander, S.R. Thorpe, J.W. Baynes, G. Navis, R.O. Gans, A.J. Smit, Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients, J. Am. Soc. Nephrol. 2005 Dec;16(12):3687-93.10.1681/ASN.200502014416280473Search in Google Scholar

15. R.P. van Waateringe, S.N. Slagter, A.P. van Beek, M.M. van der Klauw, J.V. van Vliet-Ostaptchouk, R. Graaff, A.D. Paterson, H.L. Lutgers, B.H.R. Wolffenbuttel, Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components, Diabetol. Metab. Syndr. 2017 May 30;9:42.10.1186/s13098-017-0241-1545015428572855Search in Google Scholar

16. Jaisson, S., Pietrement, C., & Gillery, P. Protein Carbamylation: Chemistry, Pathophysiological Involvement, and Biomarkers. Advances in Clinical Chemistry.. 2018;84:1-38.Search in Google Scholar

17. Jaisson, I. Kazes, A. Desmons, F. Fadel, J.B. Oudart, I.C. Santos-Weiss, H. Millart, F. Toure, P. Rieu, P. Gillery, Homocitrulline as marker of protein carbamylation in hemodialyzed patients, Clin. Chim. Acta. 2016 Sep 1;460:5-10.10.1016/j.cca.2016.06.00927302313Search in Google Scholar

18. L. Gorisse, C. Pietrement, V. Vuiblet, C.E. Schmelzer, M. Kohler, L. Duca, L. Debelle, P. Fornes, S. Jaisson, P. Gillery, Protein carbamylation is a hallmark of aging, Proc. Natl. Acad. Sci..PNAS February 2, 2016; 113 (5) 1191-119610.1073/pnas.1517096113474774326712018Search in Google Scholar

19. Delanghe, S.; Delanghe, J.R.; Speeckaert, R.; Van Biesen, W.; Speeckaert, M.M. Mechanisms and consequences of carbamoylation. Nat. Rev. Nephrol. 2017 Sep;13(9):580-593.10.1038/nrneph.2017.10328757635Search in Google Scholar

20. S. Kalim, C.A. Trottier, J.B. Wenger, J. Wibecan, R. Ahmed, E. Ankers, S.A. Karumanchi, R. Thadhani, A.H. Berg, Longitudinal changes in protein carbamylation and mortality risk after initiation of hemodialysis, Clin. J. Am. Soc. Nephrol. 2016 Oct 7;11(10):1809-1816.10.2215/CJN.02390316505378927445162Search in Google Scholar

21. E.O. Apostolov, D. Ray, A.V. Savenka, S.V. Shah, A.G. Basnakian, Chronic uremia stimulates LDL carbamylation and atherosclerosis, J. Am. Soc. Nephrol. 2010 Nov; 21(11): 1852-1857.10.1681/ASN.2010040365301400020947625Search in Google Scholar

22. E.O. Apostolov, A.G. Basnakian, E. Ok, S.V. Shah, Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease, J. Ren. Nutr. 2012 Jan;22(1):134-8.10.1053/j.jrn.2011.10.02322200430Search in Google Scholar

23. W.H. Tang, K. Shrestha, Z. Wang, A.G. Borowski, R.W. Troughton, A.L. Klein, S.L. Hazen, Protein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes, J. Card. Fail. 2013 Apr;19(4):219-24.10.1016/j.cardfail.2013.02.001363550023582087Search in Google Scholar

24. S. Jaisson, M. Kerkeni, I.C. Santos-Weiss, F. Addad, M. Hammami, P. Gillery, Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease, Clin. Chem. Lab. Med. 2015 Jan;53(1):103-10.10.1515/cclm-2014-064225153409Search in Google Scholar

25. Mogi M, Horiuchi M. Clinical interaction between brain and kidney in small vessel disease, Cardiol Res Prac. 2011; 2011:306189.Search in Google Scholar

26. Toyoda K. Cerebral small vessel disease and chronic kidney disease. J Stroke. 2015;17(1):31-7.10.5853/jos.2015.17.1.31432563325692105Search in Google Scholar

27. Seliger SL, Sarnak MJ. Subclinical vascular disease of the brain in dialysis patients. Am J Kidney Dis. 2007;50(1):8-10. Plus referenca broj 79 na strani 1310.1053/j.ajkd.2007.04.02217591520Search in Google Scholar

28. E.O. Apostolov, D. Ray, A.V. Savenka, S.V. Shah, A.G. Basnakian, Chronic uremia stimulates LDL carbamylation and atherosclerosis, J. Am. Soc. Nephrol. 2010 Nov;21(11):1852-7.10.1681/ASN.2010040365301400020947625Search in Google Scholar

29. E.O. Apostolov, A.G. Basnakian, E. Ok, S.V. Shah, Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease, J. Ren. Nutr. 2012 Jan;22(1):134-8.10.1053/j.jrn.2011.10.02322200430Search in Google Scholar

30. M. Holzer, M. Gauster, T. Pfeifer, C. Wadsack, G. Fauler, P. Stiegler, H. Koefeler, E. Beubler, R. Schuligoi, A. Heinemann, G. Marsche, Protein carbamylation renders high-density lipoprotein dysfunctional, Antioxid. Redox Signal.2011 Jun 15;14(12):2337-4610.1089/ars.2010.3640338053121235354Search in Google Scholar

31. Speer, F.O. Owala, E.W. Holy, S. Zewinger, F.L. Frenzel, B.E. Stahli, M. Razavi, S. Triem, H. Cvija, L. Rohrer, S. Seiler, G.H. Heine, V. Jankowski, J. Jankowski, G.G. Camici, A. Akhmedov, D. Fliser, T.F. Luscher, F.C. Tanner, Carbamylated low-density lipoprotein induces endothelial dysfunction, Eur. Heart J. 2014 Nov 14;35(43):3021-32.10.1093/eurheartj/ehu11124658767Search in Google Scholar

32. J. Carracedo, A. Merino, C. Briceno, S. Soriano, P. Buendia, L. Calleros, M. Rodriguez, A. Martin-Malo, P. Aljama, R. Ramirez, Carbamylated low-density lipoprotein induces oxidative stress and accelerated senescence in human endothelial progenitor cells, FASEB J. 2011 Apr;25(4):1314-22.10.1096/fj.10-17337721228221Search in Google Scholar

33. Pieniazek, K. Gwozdzinski, Carbamylation and oxidation of proteins lead to apoptotic death of lymphocytes, Chem. Biol. Interact. 2017 May 25;270:24-32.10.1016/j.cbi.2017.04.00728400100Search in Google Scholar

34. Koro, A. Hellvard, N. Delaleu, V. Binder, C. Scavenius, B. Bergum, I. Glowczyk, H.M. Roberts, I.L. Chapple, M.M. Grant, M. Rapala-Kozik, K. Klaga, J.J. Enghild, J. Potempa, P. Mydel, Carbamylated Il-37 as a modulator of the immune response, Innate Immun. 2016 Apr; 22(3): 218-229.10.1177/1753425916631404514367326878866Search in Google Scholar

35. Koro, E. Bielecka, A. Dahl-Knudsen, J.J. Enghild, C. Scavenius, J.G. Brun, V. Binder, A. Hellvard, B. Bergum, R. Jonsson, J. Potempa, A.M. Blom, P. Mydel, Carbamylation of immunoglobulin abrogates activation of the classical complement pathway, Eur. J. Immunol. 2014 Nov;44(11):3403-12.10.1002/eji.201444869423299225130613Search in Google Scholar

36. E.W. Holy, A. Akhmedov, T. Speer, G.G. Camici, S. Zewinger, N. Bonetti, J.H. Beer, T.F. Luscher, F.C. Tanner, Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo, J. Am. Coll. Cardiol. 2016 Oct 11;68(15):1664-1676.10.1016/j.jacc.2016.07.75527712780Search in Google Scholar

37. V. Binder, B. Bergum, S. Jaisson, P. Gillery, C. Scavenius, E. Spriet, A.K. Nyhaug, H.M. Roberts, I.L.C. Chapple, A. Hellvard, N. Delaleu, P. Mydel, Impact of fibrinogen carbamylation on fibrin clot formation and stability, Thromb. Haemost. 2017 May 8; 117(5): 899-910.10.1160/TH16-09-0704544260728382370Search in Google Scholar

38. Vogels SC, Emmelot-Vonk MH, Verhaar HJ, Koek HL. The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review. Maturitas. 2012;71(4):331-6.10.1016/j.maturitas.2012.01.00822318093Search in Google Scholar

39. Moodalbail DG, Reiser KA, Detre JA, Schultz RT, Herrington JD, Davatzikos C, et al. Systematic review of structural and functional neuroimaging findings in children and adults with CKD. Clin J Am Soc Nephrol CJASN. 2013; 8(8):1429-48.10.2215/CJN.11601112373191523723341Search in Google Scholar

40. Wetmore JB, Phadnis MA, Ellerbeck EF, Shireman TI, Rigler SK, Mahnken JD. Relationship between stroke and mortality in dialysis patients. Clin J Am Soc Nephrol. 2015; 10(1):80-9. 64.10.2215/CJN.02900314428440625318759Search in Google Scholar

41. Dad T, Weiner DE. Stroke and chronic kidney disease: Epidemiology, pathogenesis, and management across kidney disease stages. Semin Nephrol. 2015; 35: 311-322.10.1016/j.semnephrol.2015.06.003456769126355250Search in Google Scholar

42. Koeth, R.A.; Kalantar-Zadeh, K.; Wang, Z.; Fu, X.; Tang, W.H.; Hazen, S.L. Protein carbamylation predicts mortality in ESRD. J. Am. Soc. Nephrol. JASN. 2013 Apr 30; 24(5): 853-861.10.1681/ASN.2012030254363678723431074Search in Google Scholar

43. D’Apolito, M.; Du, X.; Zong, H.; Catucci, A.; Maiuri, L.; Trivisano, T.; Pettoello-Mantovani, M.; Campanozzi, A.; Raia, V.; Pessin, J.E.; et al. Urea-induced ros generation causes insulin resistance in mice with chronic renal failure. J. Clin. Investig. 2010 Jan;120(1):203-1310.1172/JCI37672279867419955654Search in Google Scholar

44. Koppe, L.; Nyam, E.; Vivot, K.; Manning Fox, J.E.; Dai, X.Q.; Nguyen, B.N.; Trudel, D.; Attane, C.; Moulle, V.S.; MacDonald, P.E.; et al. Urea impairs beta cell glycolysis and insulin secretion in chronic kidney disease. J. Clin. Investig. 2016; 126(9): 3598-3612.Search in Google Scholar

45. L. Gross, G. Piecha, A. Bierhaus, W. Hanke, T. Henle, P. Schirmacher, E. Ritz, Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney, Am. J. Physiol. Renal Physiol. 301: 2011;F476-485.10.1152/ajprenal.00342.201021367923Search in Google Scholar

46. L.M. Kraus, L. Gaber, C.R. Handorf, H.P. Marti, A.P. Kraus Jr., Carbamoylation of glomerular and tubular proteins in patients with kidney failure: a potential mechanism of ongoing renal damage, Swiss Med. Wkly. 2001 Mar 24;131(11-12):139-4.10.4414/smw.2001.09691Search in Google Scholar

47. M. Shaykh, A.A. Pegoraro, W. Mo, J.A. Arruda, G. Dunea, A.K. Singh, Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition, J. Lab. Clin. Med. 1999;;133(3):302-8.10.1016/S0022-2143(99)90086-0Search in Google Scholar

48. Watanabe K, Watanabe T, Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology. 2014;44:184-93.10.1016/j.neuro.2014.06.01425003961Search in Google Scholar

49. Gaxatte C, Daroux M, Bloch J, Puisieux F, Deramecourt V, Boulanger E. Cognitive impairment and chronic kidney disease: which links? Nephrol Ther. 2011;7(1):10-7.10.1016/j.nephro.2010.09.00121050832Search in Google Scholar

50. Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int. 2011;79(1):14-22.10.1038/ki.2010.336310719220861818Search in Google Scholar

51. Etgen T. Kidney disease as a determinant of cognitive decline and dementia. Alzheimer’s Res Ther. 2015;7(1):29.10.1186/s13195-015-0115-4436094325780391Search in Google Scholar

52. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15(2):123-32.10.1053/j.ackd.2008.01.010250469118334236Search in Google Scholar

53. Bugnicourt J-M, Godefroy O, Chillon J-M, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013;24(3):353-63.10.1681/ASN.201205053623291474Search in Google Scholar

54. Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. 2017; 13:1004-101210.1016/j.jalz.2017.01.018557365128253478Search in Google Scholar

55. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18(7):1272-80.10.1093/ndt/gfg07412808161Search in Google Scholar

56. Kim G.H., Kim J.E., Rhie S.J., Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases.Exp Neurobiol. 2015 Dec; 24(4): 325-340.10.5607/en.2015.24.4.325468833226713080Search in Google Scholar

57. Filiopoulos V, Hadjiyannakos D, Takouli L, Metaxaki P, Sideris V, Vlassopoulos D. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs. 2009;32(12):872-82.10.1177/03913988090320120620037892Search in Google Scholar

58. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 2009;4:47.10.1186/1750-1326-4-47278476019917131Search in Google Scholar

59. Hsieh H.L., Yang C.M. Role of redox signaling in neuroinflammation and neurodegenerative diseases. Bio-Med Res. Int. 2013;2013:18.Search in Google Scholar

60. Davies. M.J. Protein oxidation and peroxidationBiochemJ. 2016 Apr 1; 473(Pt 7): 805-825.10.1042/BJ20151227481957027026395Search in Google Scholar

61. S. Sirpal, Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease, Clin. Sci. (Lond.) 116, 2009: 681-695.10.1042/CS2008032219323651Search in Google Scholar

62. Yu G., Liang Y., Zheng S., Zhang H. Inhibition of myeloperoxidase by n-acetyl lysyltyrosylcysteine amide reduces oxidative stress-mediated inflammation, neuronal damage, and neural stem cell injury in a murine model of stroke. J. Pharmacol. Exp. Ther. 2018;364:311-322.Search in Google Scholar

63. Allen C.L., Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke. 2009;4:461-470.Search in Google Scholar

64. Vaziri, N.D.; Yuan, J.; Norris, K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am. J. Nephrol. 2013;37(1):1-6.Search in Google Scholar

65. Jing W, Jabbari B, Vaziri ND. Uremia induces upregulation of cerebral tissue oxidative/inflammatory cascade, down-regulation of Nrf2 pathway and disruption of blood brain barrier Am J Transl Res. 2018; 10(7): 2137-2147.Search in Google Scholar

66. Davis S. M, Pennypacker K. R.. Targeting Antioxidant Enzyme Expression as a Therapeutic Strategy for Ischemic Stroke.Neurochem Int. 2017; 107: 23-32.10.1016/j.neuint.2016.12.007546118928043837Search in Google Scholar

67. Eknoyan, G.; Beck, G.J.; Cheung, A.K.; Daugirdas, J.T.; Greene, T.; Kusek, J.W.; Allon, M.; Bailey, J.; Delmez, J.A.; Depner, T.A.; et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9.10.1056/NEJMoa02158312490682Search in Google Scholar

68. Handley RR, Reid SJ, Brauning R, Maclean P, Mears ER, Fourie I, Patassini S, Cooper GJS, Rudiger SR, McLaughlan CJ, Verma PJ, Gusella JF, MacDonald ME, Waldvogel HJ, Bawden CS, Faull RLM, Snell RG. Brain urea increase is an early Huntington’s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases. Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11293-E11302.10.1073/pnas.1711243115574818029229845Search in Google Scholar

69. Meijers, B.; Vanholder, R. Hemo revisited: Why kt/vurea only tells part of the story. J. Am. Soc. Nephrol. JASN. 2016 Nov;27(11):3235-3237.10.1681/ASN.2016040417508490027270443Search in Google Scholar

70. Meyer, T.W.; Sirich, T.L.; Fong, K.D.; Plummer, N.S.; Shafi, T.; Hwang, S.; Banerjee, T.; Zhu, Y.; Powe, N.R.; Hai, X.; et al. Kt/vurea and nonurea small solute levels in the hemodialysis study. J. Am. Soc. Nephrol. JASN. 2016 Nov; 27 (11) 3469-3478.10.1681/ASN.2015091035508489027026365Search in Google Scholar

71. M. T. Velasquez, A. Ramezani and D. S. Raj. Urea and protein carbamylation in ESRD: surrogate markers or partners in crime? Kidney International, 2015; Jun;87(6):1092-4.10.1038/ki.2015.78490307826024026Search in Google Scholar

72. Vanholder, R.; Glorieux, G.; Eloot, S. Once upon a time in dialysis: The last days of kt/v? 88, 460-465. Kidney Int. 2015 Sep;88(3):460-5.10.1038/ki.2015.155Search in Google Scholar

73. A.H. Berg, C. Drechsler, J. Wenger, R. Buccafusca, T. Hod, S. Kalim, W. Ramma, S.M. Parikh, H. Steen, D.J. Friedman, J. Danziger, C. Wanner, R. Thadhani, S.A. Karumanchi, Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure, Sci. Transl. Med. 2013 Mar 6;5(175):175ra29.10.1126/scitranslmed.3005218Search in Google Scholar

74. S. Jaisson, L. Gorisse, C. Pietrement, P. Gillery, Quantification of plasma homocitrulline using hydrophilic interaction liquid chromatography (HILIC) coupled to tandem mass spectrometry, Anal. Bioanal. Chem. 2012; 1635-1641.10.1007/s00216-011-5619-6Search in Google Scholar

75. S. Delanghe, A. Moerman, A. Pletinck, E. Schepers, G. Glorieux, W. Van Biesen, J.R. Delanghe, M.M. Speeckaert, Quantification of carbamylated albumin in serum based on capillary electrophoresis, Electrophoresis. 2017; 2135-2140.10.1002/elps.201700068Search in Google Scholar

76. Desmons, S. Jaisson, C. Pietrement, P. Rieu, A. Wynckel, P. Gillery, Homocitrulline: a new marker for differentiating acute from chronic renal failure, Clin. Chem. Lab. Med. 2016 Jan;54(1):73-9.10.1515/cclm-2015-0398Search in Google Scholar

77. Kwan, J. T., Carr, E. C., Bending, M. R., and Barron, J. L. Determination of carbamylated hemoglobin by highperformance liquid chromatography. Clinical Chemistry, 1990; 36(4):607-610.10.1093/clinchem/36.4.607Search in Google Scholar

78. Stim, J., Shaykh, M., Anwar, F., Ansari, A., Arruda, J. A., and Dunea, GFactors determining hemoglobin carbamylation in renal failure. Kidney Int. 1995;48(5) :1605-1610.10.1038/ki.1995.454Search in Google Scholar

79. Tarif, N., Shaykh, M., Stim, J., Arruda, J. A., and Dunea, G. Carbamylated hemoglobin in hemodialysis patients. Am J Kidney Dis 1997 Sep;30(3):361-5.10.1016/S0272-6386(97)90280-8Search in Google Scholar

80. Laaksonen S, Metsärinne K, Voipio-Pulkki LM, et al. Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 2002;25:884-90.10.1002/mus.1015912115978Search in Google Scholar

81. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC. Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry. 2006;77:548-51.10.1136/jnnp.2005.079988207749516543542Search in Google Scholar

82. American Academy of Neurology guideline summary for clinicians: detection, diagnosis and management of dementia. 2013. http://tools.aan.com/professionals/practice/pdfs/dementia_guideline.Search in Google Scholar

83. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. American Journal of Kidney Diseases 2002; 39(2):S14-S266.2002;Search in Google Scholar

84. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD American Journal of Kidney Diseases. 2014; 63( 5) : 713-735.10.1053/j.ajkd.2014.01.416Search in Google Scholar

85. Juncos L.A., Chandrashekar K., Juncos L.I. Cognitive Impairment/Dementia in Chronic Renal Disease. In: Gargiulo P., Mesones-Arroyo H. (eds) Psychiatry and Neuroscience Update. 2017; Vol. II. Springer, Cham10.1007/978-3-319-53126-7_36Search in Google Scholar

86. Hays R, Kallich J, Mapes D, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF™), Version 1.3: A Manual for Use and Scoring. Santa Monica, CA: RANDP-, 19947994.Search in Google Scholar

87. Petersen RC. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227-3410.1056/NEJMcp0910237Search in Google Scholar

88. Vicenzini E., Ricciardi M.C., Altieri M., Puccinelli F., Bonaffini N., Di Piero V., Lenzi G.L. Cerebrovascular reactivity in degenerative and vascular dementia: A transcranial doppler study. Eur. Neurol. 2007;58:84-89Search in Google Scholar

89. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.10.1016/0022-3956(75)90026-6Search in Google Scholar

90. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660.10.1212/WNL.53.8.1660Search in Google Scholar

91. Shende VS, Sharma RD, Pawar SM, Waghmare SN. A study of median nerve entrapment neuropathy at wrist in uremic patients. Indian J Nephrol. 2015. 25:229-33.10.4103/0971-4065.144425449547726199474Search in Google Scholar

92. Issar T, Arnold R, Kwai NCG, et al. The utility of the Total Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease: A validation study. Clin Neurophysiol. 2018;129:889-94.10.1016/j.clinph.2018.02.12029547762Search in Google Scholar

93. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64:199-207.10.1212/01.WNL.0000149522.32823.EA15668414Search in Google Scholar

94. Smyth B, et al. Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol BMJ Open. 2019 Jan 15;9(1):e023736.10.1136/bmjopen-2018-023736634042430782714Search in Google Scholar

95. Doulgerakis D, Moyssakis I, Kapelios CJ, Eleftheriadou I, Chorepsima S, Michail S, Tentolouris N. Cardiac autonomic neuropathy predicts all-cause and cardiovascular mortality in patients with end-stage renal failure: a 5- year prospective study. Kidney Int Rep. 2017; 02:686-69410.1016/j.ekir.2017.03.002567862829142986Search in Google Scholar

96. Badarau S, Siriopol D, Drugus D, et al. Electrocardiogram abnormalities and heart rate variability in predicting mortality and cardiovascular events among hemodialyzed patients. Int Urol Nephrol. 2015;47:1703-1708.10.1007/s11255-015-1063-426329736Search in Google Scholar

97. Vaziri, N.D. Effect of synbiotic therapy on gut-derived uremic toxins and the intestinal microbiome in patients with ckd. Clin. J. Am. Soc. Nephrol. CJASN 2016, 11, 199-201.10.2215/CJN.13631215474105226772192Search in Google Scholar

98. Ranganathan N. Reality of “Enteric Dialysis ®” with Probiotics and Prebiotics to Delay the Need of Conventional Dialysis. J Nephrol Ther. 2018, 8: 319.10.4172/2161-0959.1000319Search in Google Scholar

99. Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy? Nephron. 2017;135(3):201-206.10.1159/00045367327960172Search in Google Scholar

100. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18(7):1272-80.10.1093/ndt/gfg07412808161Search in Google Scholar

101. J.J. Carrero, P. Stenvinkel, L. Cuppari, T.A. Ikizler, K. Kalantar-Zadeh, G. Kaysen, W.E. Mitch, S.R. Price, C. Wanner, A.Y. Wang, P. ter Wee, H.A. Franch, Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM), J. Ren. Nutr. 2013 Mar;23(2):77-90.10.1053/j.jrn.2013.01.00123428357Search in Google Scholar

102. S. Kalim, G. Ortiz, C.A. Trottier, J.J. Deferio, S.A. Karumanchi, R.I. Thadhani, A.H. Berg, The effects of parenteral amino acid therapy on protein carbamylation in maintenance hemodialysis patients, J. Ren. Nutr. 2015 Jul;25(4):388-92.10.1053/j.jrn.2015.01.019446957025753604Search in Google Scholar

103. Stosovic M, Nikolic A, Stanojevic M, et al. Nerve conduction studies and prediction of mortality in hemodialysis patients. Ren Fail 2008;30:695-9.10.1080/0886022080221289018704818Search in Google Scholar

104. Jurcić D, Bilić A, Schwarz D, et al. Clinical course of uremic neuropathy in long-term hemodialysis. Coll Antropol 2008;32:771-5.Search in Google Scholar

105. Ho DT, Rodig NM, Kim HB, Lidov HGW, Shapiro FD, Raju GP, Kang PB. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatr Transplant 2012; 16: E296-E300.10.1111/j.1399-3046.2011.01630.x331173322188489Search in Google Scholar